Net profit of Alkem Laboratories rose 11.10% to Rs 765.06 crore in the quarter ended September 2025 as against Rs 688.64 crore during the previous quarter ended September 2024. Sales rose 17.17% to Rs 4000.99 crore in the quarter ended September 2025 as against Rs 3414.67 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales4000.993414.67 17 OPM %23.0122.05 - PBDT989.44859.17 15 PBT895.83780.26 15 NP765.06688.64 11 Powered by Capital Market - Live News

 Alkem Foundation, the Corporate Social Responsibility (CSR) arm of Alkem Laboratories (Alkem), and Indian Institute of Technology Bombay (IIT Bombay) today announced a strategic collaboration to set up a first-of-its-kind research centre in India dedicated to immuno-therapeutics and regenerative medicines. Under this collaboration, Alkem Foundation will fund the establishment of �Alkem Centre for Advanced Research and Development of Applied Immuno-Therapeutics and Regenerative Medicines� in the IIT Bombay campus. This is a pioneering step in fostering cutting-edge research and innovation in complex disease areas, which have significant unmet medical needs. Alkem Foundation will contribute a substantial 20-25% of its cumulative CSR obligations over seven years on this research centre. This is the first industry-academia collaboration in the country, initiated through the CSR route, for advancing research in the areas of immuno-therapeutics and regenerative medicines. The partnership brings together Alkem`s pharmaceutical industry insights and experience in developing healthcare solutions, and IIT Bombay`s expertise in biomedical engineering, biosciences, and translational research, along with a pool of globally trained faculty, to create a distinctive innovation and translation ecosystem. Powered by Capital Market - Live News

Alkem Laboratories will hold a meeting of the Board of Directors of the Company on 13 November 2025.Powered by Capital Market - Live News

Alkem Laboratories announced the launch of Pertuza injection 420mg/14mL, a pertuzumab biosimilar, in India for the treatment of HER2-positive breast cancer. Alkem`s Pertuza is an affordable, indigenously-developed and manufactured biosimilar of pertuzumab. In the pivotal phase 3 clinical trial, Alkem`s pertuzumab biosimilar, developed by its biotech subsidiary, demonstrated equivalence in efficacy, safety, and immunogenicity to the reference product of the innovator. Accessibility of pertuzumab in India has remained a significant challenge and only limited HER2-postive breast cancer patients are able to use it in their treatment due to cost barriers. By bringing an affordable pertuzumab biosimilar, backed by research, regulatory-compliant manufacturing, and strong oncology distribution network, Alkem strives to ensure scientific credibility and improved accessibility. Powered by Capital Market - Live News

Alkem Laboratories announced the launch of Olesoft Trucera moisturizing lotion, an advanced science-led formulation designed to restore hydration, strengthen the skin barrier, and soothe skin flare ups with an inside out approach. Olesoft Trucera contains N-Palmitoyl Serinol that stimulates the skin`s natural ceramide production, a potent blend of five ceramides to lock in moisture and support the skin barrier`s function, and dual oat-extract actives along with Niacinamide to provide anti-inflammatory benefits. Olesoft Trucera will be available on prescription, so consult a doctor before using. Powered by Capital Market - Live News